Clinical Research Directory
Browse clinical research sites, groups, and studies.
Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
Sponsor: First People's Hospital of Shenyang
Summary
The purpose of this clinical trial is to understand and evaluate the clinical efficacy and safety of Daphnetin Capsule in patients with vascular cognitive impairment. Changes in the Vascular Dementia Assessment Scale-cog(VADAS-cog) at 6 months were evaluated. Although Daphnetin has a dual neurovascular protective effect, however, there is still a lack of relevant high-quality studies on its role in patients with vascular cognitive impairment, especially in patients with vascular cognitive impairment in non-dementia (VCI-ND), whether it has a role in improving cognitive status needs to be urgently explored in high-quality clinical studies. Researchers are comparing Daphnetin to placebo (a drug-free analog) to see if Daphnetin is effective in treating vascular cognitive impairment. Participants will take either Daphnetin or placebo daily for six months, with follow-up visits every three months and completion of a case report form.
Official title: Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia - A Randomized, Double-blind, Placebo-controlled Study
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
206
Start Date
2025-07-07
Completion Date
2026-04-30
Last Updated
2025-08-28
Healthy Volunteers
No
Conditions
Interventions
Daphnetin Capsule
Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .
Placebo
The placebo is a Daphnetin Capsule simulants
Locations (1)
Shenyang First People's Hospital
Shenyang, Liaoning, China